Skip to Content

GlaxoSmithKline PLC ADR GSK

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Glaxo Posts Largely In Line Q4 but Signals Dividend Cut With Likely 2022 Consumer Unit Divestment

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

GlaxoSmithKline reported fourth-quarter results largely in line with our expectations, and we don’t expect any major changes to our fair value estimate. Importantly, the company confirmed the separation of the consumer business in 2022, and the combined dividend of the remaining core biopharma and the new consumer company would be lower than the current dividend. The magnitude of the dividend cut will likely be communicated in June along with long-term growth expectations. We believe the cut will be substantial, potentially as much as a 30% to 40% reduction, since Glaxo has messaged a return to a progressively increasing dividend following 2022 for the biopharma group, which will be easier to achieve if the 2022 cut is larger. From an operational standpoint, we don’t view the dividend cut as signaling an unhealthy business but rather the firm's desire to invest more in the biopharma’s innovative pipeline. With less dividend payments, we expect investment in innovation to increase and ultimately lead to faster earnings growth and eventual dividend increases after 2022. The increased investments in innovation should further support Glaxo’s pipeline and wide moat.

Read Full Analysis

Company Profile

Business Description

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

Contact
980 Great West Road
Brentford, Middlesex, TW8 9GS, United Kingdom
T +44 2080475000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 99,437

Related